Schering stock falls on profits

Schering-Plough posted strong profits and double-digit sales growth yesterday--but its stock plunged. So what gives?

Well, it's true that the drug maker doubled profits only on one-time gains; excluding those, the company's earnings per share were only 28 cents, two pennies lower than analysts had expected. And there's the rub: Expectations. After years of low expectations, Merck's profits rose 62 percent; its stock rose $1.53 to $54.64. After two years of strong performance and high expectations, Schering's stock took a $4.37 hit, falling to $28.34.

Miss the expectations mark and people start asking questions, too. Such as, how will Schering-Plough make up for the slowdown in growth of its cholesterol drugs Vytorin and Zetia (both joint ventures with Merck)? Can it profitably absorb Organon BioSciences later this year? And if there's on thing Wall Street doesn't like, it's questions.

- see the release from Schering-Plough
- read this report from CNN Money
- read the New York Times article

Related Articles:
Schering-Plough: A good company to work for. Report
Repeat after me: Stock prices will grow in autumn. Report
CEO Hassan bullish on Schering-Plough. Report
Schering-Plough buys Organon. Report
Schering-Plough buoyed by asenapine data. Report

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Patients with epithelioid sarcoma previously had no targeted treatment options, but that'll change with Epizyme's approval for Tazverik.

With federal prosecutors laying waste to Insys' executive team, one big domino was still left to fall: Founder and former CEO John Kapoor.